Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Alzamend Neuro, Inc.

  • ATLANTA, Georgia
  • Public · NASDAQ: ALZN
  • 7 employees
$4.2MMarket cap
-$4.5MNet income
7Employees
ALZNNASDAQ
2021IPO

About Alzamend Neuro, Inc.

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Net income
-$4.5M
Total assets
$4.6M
Market cap
$4.2M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: ALZN

15-minute delayed · data by Polygon.io

Market cap
$4.2M
Open
Day range
Prev close
Volume
IPO date
Jun 15, 2021

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review Alzamend Neuro, Inc..

Write a review
Explore

Similar companies

Browse all →